Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib November 22, 2021 A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... June 19, 2019 Woman Donates 500 Care Packages To Breast Cancer Patients October 11, 2021 New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... May 20, 2021 Load more HOT NEWS Toddler Hailed A Hero After He Saved His Family From Fire... Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... Do Birth Control Pills Impact My Cancer Risk? PICOS Score May Help in Identification of Patients with Brain Metastasis...
